CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation

Inclusion Criteria:

1. Male or female 18 years of age or older

2. A history of recurrent pericarditis* with stable disease and currently being treatedwith an IL-1 blocker, scheduled to be discontinued. Stable disease is defined as:

• treatment with an IL-1 blocker for at least 12 months;

• free of pericarditis recurrence for at least 6 months and this recurrence, ifpresent, must have occurred in the setting of an interruption or tapering of anIL-1 blocker; and

• treatment with an unchanged dose and regimen of on an IL-1 blocker for at least 3 months prior to randomization.

3. Pericarditis pain pain ≤ 2 on the 11-point Numerical Rating Scale (NRS) for at leastthe prior 7 days

4. C-Reactive Protein (CRP**) < 1.0 mg/dL within the 7 days of screening prior to Day 1 (Visit 1)

5. Male patients with partners of childbearing potential who have had a vasectomy orwho are willing to use double barrier contraception methods during the conduct ofthe trial and for 2 months after the last dose of trial therapy

6. Women of childbearing potential willing to use an acceptable method of contraceptionstarting with trial drug administration and for a minimum of 2 months after trialcompletion. Otherwise, women must be postmenopausal (at least 1 year absence ofvaginal bleeding or spotting and confirmed by follicle stimulating hormone [FSH] ≥40mIU/mL [or ≥ 40 IU/L] if less than 2 years postmenopausal) or be surgically sterile.

Exclusion Criteria:

1. Pericarditis recurrence(s) during IL-1 blocker treatment without interruption ortapering of the IL-1 blocker

2. Diagnosis of pericarditis that is secondary to specific prohibited etiologies,including tuberculosis (TB); neoplastic, purulent, or radiation etiologies;post-thoracic blunt trauma (e.g., motor vehicle accident); systemic autoimmunedisease (e.g., systemic lupus erythematosus)

3. Primary diagnosis of myocarditis (diagnosis of myopericarditis is accepted)

4. Estimated glomerular filtration rate (eGFR) < 30 mL/min at baseline

5. Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5times the upper limit of normal (ULN) or ALT or AST > 3x ULN plus bilirubin > 2x ULN

6. Sepsis, defined as documented bacteremia at baseline or other untreated oruncontrolled bacterial infection*

7. Prior history of sustained ventricular arrhythmia(s)

8. History of diagnosed long QT syndrome

9. QTc interval > 500 msec at baseline

10. Showing suicidal tendency, as defined by answering "yes" to question 4 or 5 of theColumbia Suicide Severity Rating Scale (C-SSRS), administered at baseline

11. Currently participating in any research trial involving investigational drugs ordevices

12. Inability or unwillingness to give informed consent

13. Ongoing drug or alcohol abuse in the opinion of the investigator

14. On any cannabinoid during the past month and unwilling to stay abstinent from allcannabis products for the duration of the trial

15. Pregnant or breastfeeding

16. Current diagnosis of cancer, with the exception of non-melanoma skin cancer

17. Any factor, which would make it unlikely that the patient can comply with the trialprocedures

18. Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment

19. Has received systemic immunomodulatory agents prior to randomization:

20. Methotrexate (within 2 weeks)

21. Azathioprine (within 24 weeks)

22. Cyclosporine (within 24 weeks)

23. Intravenous immune globulin (IVIG) (within 8 weeks)

24. Corticosteroids (within 4 weeks).